Drugs / Avmacol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03402230 | Feb 2018 → Jan 2020 | cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 0 | NCT03182959 | Apr 2017 → Jan 2020 | head and neck squamous cell carcinoma, hyperplasia, in situ carcinoma, preneoplastic lesion +1 | University of Arizona | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Avmacol | “broccoli sprout/broccoli seed extract supplement (Avmacol)” NCT03402230 ↗ |
| Action | Activate | “This study hypothesizes that nuclear factor erythroid 2-related factor 2 (NRF2) pathway activation in oral epithelium can be induced by administering Avmacol® to patients...” NCT03182959 ↗ |
| Route | Oral | “Given PO” NCT03402230 ↗ |